simendan has been researched along with enoximone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bozkurt, AK; Köksal, C; Köseoğlu, S; Süzer, O | 1 |
| Bak, I; Borbély, A; Edes, I; Haikala, H; Levijoki, J; Papp, Z; Pollesello, P; Szilágyi, S; Tósaki, A | 1 |
| Fuhrmann, JT; Rauwolf, T; Schmeisser, A; Schoen, SP; Schulze, MR; Strasser, RH; Weinbrenner, C; Wunderlich, C | 1 |
| Buerke, M; Prondzinsky, R | 1 |
| Rijnders, BJ | 1 |
| Berthelsen, PG | 1 |
| Beute, J | 1 |
| Ebner, B; Hönisch, A; Strasser, RH; Theuring, N; Wagner, C; Weinbrenner, C | 1 |
| Caliskan, K; Delnoij, TS; Donker, DW; Maessen, JG; Weerwind, PW; Wetzels, AE | 1 |
| Buerke, M; Haerting, J; Hirsch, K; Prondzinsky, R; Thiele, H; Unverzagt, S; Wachsmuth, L; Werdan, K | 1 |
| Beutlhauser, T; Erb, J; Feldheiser, A; Grubitzsch, H; Schuster, B; Spies, C; Treskatsch, S | 1 |
| Calabrò, MG; Covello, RD; Greco, M; Greco, T; Landoni, G; Morelli, A; Pasin, L; Zangrillo, A | 1 |
| Frantz, S; Henrich, EC; Prondzinsky, R; Schumann, J; Strobl, H; Thiele, H; Unverzagt, S; Weiche, S; Werdan, K | 1 |
| Efremov, L; Frantz, S; Mikolajczyk, R; Schumann, J; Sedding, D; Tongers, J; Uhlig, K | 1 |
4 review(s) available for simendan and enoximone
| Article | Year |
|---|---|
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Enoximone; Humans; Hydrazones; Myocardial Infarction; Nitric Oxide; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2014 |
A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.
Topics: Bayes Theorem; Cardiac Surgical Procedures; Critical Illness; Dobutamine; Enoximone; Humans; Hydrazones; Milrinone; Pyridazines; Simendan; Vasodilator Agents | 2015 |
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cause of Death; Dobutamine; Enoximone; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Nitric Oxide; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2018 |
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cause of Death; Dobutamine; Enoximone; Epinephrine; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Nitric Oxide; Placebos; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents | 2020 |
2 trial(s) available for simendan and enoximone
| Article | Year |
|---|---|
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Topics: Aged; Cardiotonic Agents; Coronary Care Units; Enoximone; Female; Hemodynamics; Hospital Mortality; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Pyridazines; Shock, Cardiogenic; Simendan | 2008 |
Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiomyopathies; Cardiotonic Agents; Coronary Artery Bypass; Double-Blind Method; Enoximone; Female; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2014 |
8 other study(ies) available for simendan and enoximone
| Article | Year |
|---|---|
Comparison of enoximone, amrinone, or levosimendan enriched St. Thomas' hospital cardioplegic solutions used for myocardial preservation in isolated guinea pig hearts.
Topics: Amrinone; Animals; Bicarbonates; Calcium Chloride; Cardioplegic Solutions; Cardiotonic Agents; Enoximone; Female; Guinea Pigs; Heart; Heart Arrest, Induced; Hydrazones; In Vitro Techniques; Magnesium; Male; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; Organ Preservation; Phosphodiesterase Inhibitors; Potassium Chloride; Pyridazines; Simendan; Sodium Chloride | 2002 |
Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Enoximone; Female; Guinea Pigs; Hydrazones; In Vitro Techniques; Isoenzymes; Isometric Contraction; Male; Myocardial Contraction; Myocytes, Cardiac; Myofibrils; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Simendan; Substrate Specificity | 2005 |
Levosimendan in cardiogenic shock: better than enoximone!
Topics: Cardiotonic Agents; Enoximone; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan | 2008 |
Evaluation of 30-day mortality of levosimendan versus enoximone.
Topics: Cardiotonic Agents; Enoximone; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Shock, Cardiogenic; Simendan; Time Factors | 2009 |
Levosimendan or enoximone in refractory cardiogenic shock?
Topics: Cardiotonic Agents; Enoximone; Humans; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Shock, Cardiogenic; Simendan | 2009 |
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Topics: Cardiotonic Agents; Enoximone; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan | 2009 |
Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition.
Topics: Animals; Cardiotonic Agents; Enoximone; Hemodynamics; Hydrazones; Immunoblotting; KATP Channels; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Pyridazines; Rats; Rats, Wistar; Signal Transduction; Simendan | 2010 |
Peripheral venoarterial extracorporeal life support despite impending left ventricular thrombosis: a bridge to resolution.
Topics: Advanced Cardiac Life Support; Anticoagulants; Biopsy; Enoximone; Extracorporeal Circulation; Heparin; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Shock, Cardiogenic; Simendan; Vasodilator Agents; Venous Thrombosis; Ventricular Dysfunction, Left | 2013 |